Uric Acid Reducer Recalled

Allopurinol tablets were recalled by Cardinal Healthcare due to exposure to temperatures outside labeled storage conditions, according to the January 3, 2024, US Food and Drug Administration (FDA) Enforcement Report.

The voluntary recall affected 1 unit of 500-count allopurinol tablets, 300 mg (NDC 55111-730-05), from batch L100813. The tablets were manufactured by Dr. Reddy’s Laboratories, Shreveport, Louisiana, and distributed in the US.

Cardinal Healthcare voluntarily initiated the recall January 26, 2022. The FDA designated the recall Class II on December 26, 2023. The classification communicates that use of the medication may cause temporary or medically reversible adverse health consequences or a remote possibility of serious harm.

Per the January 3, 2024, FDA Enforcement Report, the recall has been completed.

Allopurinol is a uric acid reducer available with a prescription to treat patients with gout, kidney stones, and leukemia, lymphoma and malignancies with elevations of uric acid levels.